Intelligent Bio Solutions Inc
NASDAQ:INBS
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Intelligent Bio Solutions Inc
NASDAQ:INBS
|
5.2m USD |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
199.2B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
175.5B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
146.1B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
124.4B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
111.8B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
47.6B EUR |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
52.1B USD |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
52B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.1B USD |
Loading...
|
|
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
38.2B USD |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
Intelligent Bio Solutions Inc
Glance View
GBS, Inc. operates as a biosensor diagnostic technology company. The company is headquartered in New York City, New York and currently employs 12 full-time employees. The company went IPO on 2020-12-23. The firm is developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. The firm's Intelligent Bio Solutions is a biosensor platform, which is engaged in developing and launching diagnostic tests urgently needed to help people living with chronic diseases. The firm's subsidiary Intelligent Fingerprinting is engaged in the advancement of portable drugs of abuse testing through the analysis of fingerprint sweat. The test is non-invasive, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The firm also offers laboratory confirmation services. The system has applications within many sectors in safety-critical industries such as construction, transport and logistics firms, drug treatment organizations, as well as the United Kingdom (UK) coroners.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Intelligent Bio Solutions Inc is 43.1%, which is above its 3-year median of 37.9%.
Over the last 3 years, Intelligent Bio Solutions Inc’s Gross Margin has increased from 39.6% to 43.1%. During this period, it reached a low of 20.9% on Dec 31, 2023 and a high of 58.8% on Mar 31, 2025.
